Bank of America Forecasts Strong Price Appreciation for Liquidia (NASDAQ:LQDA) Stock

Liquidia (NASDAQ:LQDA) had its target price increased by stock analysts at Bank of America from $79.00 to $92.00 in a report released on Thursday,Benzinga reports. The brokerage currently has a “neutral” rating on the stock. Bank of America‘s target price indicates a potential upside of 16.77% from the company’s current price.

Several other brokerages have also recently issued reports on LQDA. BTIG Research upped their target price on Liquidia from $109.00 to $111.00 and gave the company a “buy” rating in a report on Wednesday. HC Wainwright set a $36.00 target price on shares of Liquidia in a report on Friday, July 24th. Lifesci Capital restated a “market perform” rating and set a $90.00 price target on shares of Liquidia in a report on Wednesday. Raymond James Financial reiterated a “strong-buy” rating and issued a $68.00 price objective on shares of Liquidia in a research report on Thursday, June 4th. Finally, Oppenheimer set a $75.00 target price on Liquidia in a research report on Friday, June 5th. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $91.08.

Liquidia Price Performance

Liquidia stock opened at $78.79 on Thursday. The company has a fifty day simple moving average of $78.22 and a 200-day simple moving average of $54.77. The firm has a market capitalization of $7.01 billion, a price-to-earnings ratio of 562.83 and a beta of 0.58. The company has a quick ratio of 2.03, a current ratio of 2.22 and a debt-to-equity ratio of 1.18. Liquidia has a 52-week low of $21.15 and a 52-week high of $93.61.

Liquidia (NASDAQ:LQDA) last posted its quarterly earnings results on Wednesday, August 12th. The company reported $0.74 earnings per share for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.02). Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The business had revenue of $171.68 million for the quarter, compared to analyst estimates of $168.48 million. During the same quarter in the previous year, the firm posted ($0.49) earnings per share. The business’s revenue was up 1842.1% compared to the same quarter last year. On average, equities analysts anticipate that Liquidia will post 3.02 EPS for the current fiscal year.

Insider Activity at Liquidia

In other Liquidia news, Director Paul B. Manning sold 200,000 shares of the business’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $63.91, for a total value of $12,782,000.00. Following the completion of the transaction, the director owned 716,311 shares in the company, valued at $45,779,436.01. The trade was a 21.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Stephen M. Bloch sold 242,269 shares of the company’s stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $70.43, for a total value of $17,063,005.67. Following the sale, the director directly owned 1,176,184 shares in the company, valued at $82,838,639.12. This represents a 17.08% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 1,781,861 shares of company stock valued at $124,407,112 in the last three months. 25.60% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Liquidia

Institutional investors and hedge funds have recently made changes to their positions in the stock. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Liquidia in the 4th quarter valued at about $25,000. Covestor Ltd increased its position in Liquidia by 41.9% in the 4th quarter. Covestor Ltd now owns 1,216 shares of the company’s stock valued at $42,000 after acquiring an additional 359 shares during the period. NewEdge Advisors LLC purchased a new stake in Liquidia during the 2nd quarter valued at approximately $25,000. Globeflex Capital L P acquired a new stake in Liquidia during the 2nd quarter worth approximately $175,000. Finally, Fluent Financial LLC purchased a new position in shares of Liquidia in the 2nd quarter valued at approximately $287,000. 64.54% of the stock is owned by institutional investors and hedge funds.

Liquidia News Summary

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: YUTREPIA sales accelerated: Net product sales reached approximately $170.4 million, up 31% sequentially, while total revenue of $171.7 million exceeded the $168.5 million consensus estimate. Management said demand for the inhaled lung-disease treatment continues to grow, with about 5,900 prescriptions and more than 5,000 patients treated since launch. Liquidia Corporation Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Profitability and liquidity improved: Liquidia reported $74.7 million of net income, $96.3 million of adjusted EBITDA and its fourth consecutive quarter of improving profitability. Cash increased to approximately $284.2 million, supporting commercialization and development efforts.
• Positive Sentiment: Analyst targets increased: Needham raised its price target from $70 to $110 and BTIG lifted its target from $109 to $111; both firms maintain Buy ratings. Lifesci Capital reiterated Market Perform with a $90 target. Analyst price-target updates
• Neutral Sentiment: Future investment remains elevated: Liquidia is advancing 10 clinical studies for YUTREPIA and L606, but research and development spending rose to $17.2 million from $6.0 million a year earlier. Management reaffirmed its goal of exceeding $1 billion in net revenue in 2027.
• Negative Sentiment: EPS slightly missed expectations: Diluted earnings were $0.74 per share versus the $0.76 consensus estimate cited by several reports, even though the result improved sharply from a $0.49 loss in the prior-year quarter. The earnings miss likely outweighed the revenue beat for short-term traders.
• Negative Sentiment: Valuation and insider selling may pressure the stock: Liquidia trades at a very high earnings multiple after a major run-up, creating a greater risk of profit-taking. Recent data also shows substantially more insider selling than buying, which may weigh on investor sentiment.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).